Drug Database
Back to search

France· FR:67650090

TAKHZYRO 150 mg, solution injectable en seringue préremplie

A lanadelumab product containing lanadélumab, registered in France by TAKEDA PHARMACEUTICALS INTERNATIONAL (IRLANDE). The same ATC class is registered in 15 of our 19 countries.

ATC B06AC05

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedTAKHZYRO 150 mg, solution injectable …ATCB06AC05REGISTER NO.FR:67650090PACKS LISTED1CHECKEDSeptember 12, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about lanadélumabAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Lanadelumab is registered in 15 of 19 countries.

Countries holding a registration under ATC B06AC05 (lanadelumab), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 10 of them publish a price we can compare per daily dose
Search lanadelumab products by name

Lanadelumab · ATC B06AC05

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of lanadelumab costs, country by country.

Normalised to the WHO defined daily dose (21.4 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Lanadelumab · price per daily dose (21.4 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$857.11
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
LANADÉLUMAB
Manufacturer
TAKEDA PHARMACEUTICALS INTERNATIONAL (IRLANDE)
Country
France (FR)
ATC code
B06AC05
ATC class
Lanadelumab
Defined daily dose
21.4 mg, P
Reimbursed
No
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

  • cip13
    3400930280300
    1 seringue(s) préremplie(s) en verre de 1 ml

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Lanadelumab in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All lanadelumab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Takhzyro
  • Liechtenstein · Takhzyro
  • Norway · Takhzyro

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/eab1af61-5726-4ade-b0f0-a581c2f9e98d
GET /v1/drugs/eab1af61-5726-4ade-b0f0-a581c2f9e98d?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "67650090",
  "date_amm": "2023-11-15",
  "type_amm": "Procédure centralisée",
  "numero_ue": "EU/1/18/1340",
  "substance": "LANADÉLUMAB",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "solution injectable",
  "voies_administration": "sous-cutanée",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Non"
}
API referenceMCP serverPlans

See everything about lanadelumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console